Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$3.69
+3.1%		$2.94
$2.34
▼
$15.00
$57.35M2.53463,975 shs448,567 shs
Better Choice Company Inc. stock logo
SRXH
Better Choice
$1.54
-2.4%		$14.86
$0.96
▼
$42.61
$31.24M0.821.93 million shs316,117 shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$2.23
-2.2%		$2.19
$0.95
▼
$9.08
$84.14M1.431.48 million shs579,149 shs
Upexi, Inc. stock logo
UPXI
Upexi
$1.02
-2.3%		$0.89
$0.54
▼
$7.75
$79.96M-0.213.69 million shs1.96 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
+8.48%+15.86%+32.59%+42.06%-44.75%
Better Choice Company Inc. stock logo
SRXH
Better Choice
+4.64%-3.07%-0.63%-78.27%-92.98%
Tharimmune, Inc. stock logo
THAR
Tharimmune
0.00%0.00%+21.93%-14.93%-22.97%
Upexi, Inc. stock logo
UPXI
Upexi
-2.80%0.00%+22.18%+20.93%-81.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$3.69
+3.1%		$2.94
$2.34
▼
$15.00
$57.35M2.53463,975 shs448,567 shs
Better Choice Company Inc. stock logo
SRXH
Better Choice
$1.54
-2.4%		$14.86
$0.96
▼
$42.61
$31.24M0.821.93 million shs316,117 shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$2.23
-2.2%		$2.19
$0.95
▼
$9.08
$84.14M1.431.48 million shs579,149 shs
Upexi, Inc. stock logo
UPXI
Upexi
$1.02
-2.3%		$0.89
$0.54
▼
$7.75
$79.96M-0.213.69 million shs1.96 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
+8.48%+15.86%+32.59%+42.06%-44.75%
Better Choice Company Inc. stock logo
SRXH
Better Choice
+4.64%-3.07%-0.63%-78.27%-92.98%
Tharimmune, Inc. stock logo
THAR
Tharimmune
0.00%0.00%+21.93%-14.93%-22.97%
Upexi, Inc. stock logo
UPXI
Upexi
-2.80%0.00%+22.18%+20.93%-81.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
2.00
Hold$7.78110.65% Upside
Better Choice Company Inc. stock logo
SRXH
Better Choice
0.00
N/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.00
SellN/AN/A
Upexi, Inc. stock logo
UPXI
Upexi
2.00
Hold$4.65357.68% Upside

Current Analyst Ratings Breakdown

Latest SRXH, UPXI, THAR, and HYPD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$7.30 ➝ $8.45
9/4/2026
Upexi, Inc. stock logo
UPXI
Upexi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/1/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
8/18/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D)
8/13/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$6.60 ➝ $7.10
8/12/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/11/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.30
7/14/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/1/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$4.00 ➝ $6.60
7/1/2026
Upexi, Inc. stock logo
UPXI
Upexi
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$2.00 ➝ $1.30
6/24/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$1.40M40.95N/AN/A$4.73 per share0.78
Better Choice Company Inc. stock logo
SRXH
Better Choice
-$24.91M-1.25N/AN/A$4.09 per share0.38
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/A$0.68 per shareN/A
Upexi, Inc. stock logo
UPXI
Upexi
$26.14M3.06N/AN/A$1.01 per share1.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$45.31M-$6.53N/A3.45N/A416.56%-11.62%-9.96%N/A
Better Choice Company Inc. stock logo
SRXH
Better Choice
-$22.77M-$11.74N/AN/AN/A-39.83%-206.10%-60.54%N/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%N/A
Upexi, Inc. stock logo
UPXI
Upexi
-$13.68M-$0.62N/AN/AN/A-874.00%-66.70%-19.56%9/24/2026 (Estimated)

Latest SRXH, UPXI, THAR, and HYPD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/24/2026Q4 2026
Upexi, Inc. stock logo
UPXI
Upexi
-$0.11N/AN/AN/A$1.00 millionN/A
8/13/2026Q2 2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/A$0.92N/A$0.92N/A$0.36 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/AN/AN/AN/AN/A
Better Choice Company Inc. stock logo
SRXH
Better Choice
N/AN/AN/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/AN/A
Upexi, Inc. stock logo
UPXI
Upexi
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
0.06
2.34
2.34
Better Choice Company Inc. stock logo
SRXH
Better Choice
N/A
2.38
1.81
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/A
4.98
4.98
Upexi, Inc. stock logo
UPXI
Upexi
2.96
1.72
1.72

Institutional Ownership

CompanyInstitutional Ownership
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
25.84%
Better Choice Company Inc. stock logo
SRXH
Better Choice
12.64%
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.16%
Upexi, Inc. stock logo
UPXI
Upexi
5.68%

Insider Ownership

CompanyInsider Ownership
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
7.50%
Better Choice Company Inc. stock logo
SRXH
Better Choice
33.40%
Tharimmune, Inc. stock logo
THAR
Tharimmune
6.70%
Upexi, Inc. stock logo
UPXI
Upexi
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
4015.54 million14.37 millionNo Data
Better Choice Company Inc. stock logo
SRXH
Better Choice
4020.27 million1.39 millionNo Data
Tharimmune, Inc. stock logo
THAR
Tharimmune
237.73 million35.20 millionNot Optionable
Upexi, Inc. stock logo
UPXI
Upexi
13078.70 million71.62 millionOptionable

Recent News About These Companies

Upexi to Participate in FT Partners FinTech Conference 2026 on September 15th
September 8 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357612/0/en/upexi-to-participate-in-ft-partners-fintech-conference-2026-on-september-15th.html
Upexi (UPXI) Expected to Release Earnings on Wednesday
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-upexi-upxi-expected-to-release-earnings-on-wednesday-2026-08-26/
Upexi (NASDAQ:UPXI) Trading Down 9.4% - Here's What Happened
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upexi-nasdaqupxi-trading-down-94-heres-what-happened-2026-08-13/
Upexi Faces Nasdaq Non-Compliance on Minimum Bid Price
July 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/upexi-faces-nasdaq-non-compliance-on-minimum-bid-price?utm_source=marketbeat.com&utm_medium=referral
Upexi Insider Trading Activity | NASDAQ:UPXI | Benzinga
July 7, 2026  |  benzinga.comhttps://www.benzinga.com/quote/UPXI/insider-trades
Upexi Inc: Upexi Partners with Blueprint to Stake Solana Treasury Assets
June 30, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68906787-upexi-inc-upexi-partners-with-blueprint-to-stake-solana-treasury-assets-399.htm
Upexi Partners with Blueprint to Stake Solana Treasury Assets
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319588/0/en/upexi-partners-with-blueprint-to-stake-solana-treasury-assets.html
Upexi Added to Russell Microcap Index in June 2026 Reconstitution
June 26, 2026  |  quiverquant.comQ
Upexi Added to the Russell Microcap® Index
June 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/26/3318192/0/en/upexi-added-to-the-russell-microcap-index.html
Upexi, Inc. Announces Pricing of ~$19.5 Million Private Placement of Common Stock
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315259/0/en/upexi-inc-announces-pricing-of-19-5-million-private-placement-of-common-stock.html
Upexi Shareholders Reelect Board and Ratify Auditor
June 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/upexi-shareholders-reelect-board-and-ratify-auditor?utm_source=marketbeat.com&utm_medium=referral
UPXI Share News Today
May 19, 2026  |  uk.investing.comhttps://uk.investing.com/equities/grove-news/10
Upexi (UPXI) Stock Forecast & Price Target
May 15, 2026  |  investing.comhttps://www.investing.com/equities/grove-consensus-estimates
Upexi Stock Short Interest Report | NASDAQ:UPXI | Benzinga
May 15, 2026  |  benzinga.comhttps://www.benzinga.com/quote/UPXI/short-interest
Upexi (UPXI) Q3 2026 Earnings Transcript
May 15, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/05/14/upexi-upxi-q3-2026-earnings-transcript/
Upexi, Inc. Earnings Call Highlights Crypto-Fueled Volatility
May 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/upexi-inc-earnings-call-highlights-crypto-fueled-volatility?utm_source=marketbeat.com&utm_medium=referral
Upexi Net Loss Balloons to $109 Million on Solana Treasury Markdown
May 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/upexi-net-loss-balloons-109-105748225.html
Upexi Reports Fiscal Third Quarter 2026 Financial Results
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3293452/0/en/upexi-reports-fiscal-third-quarter-2026-financial-results.html
Upexi Q3 2026 earnings preview
May 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/upexi-q3-2026-earnings-preview/ar-AA22WjXO
Upexi to Present at the LD Micro Invitational XVI Conference on May 17-19
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290017/0/en/upexi-to-present-at-the-ld-micro-invitational-xvi-conference-on-may-17-19.html
Upexi Provides Periodic Update to its Share Repurchase Program
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288819/0/en/upexi-provides-periodic-update-to-its-share-repurchase-program.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hyperion DeFi stock logo

Hyperion DeFi NASDAQ:HYPD

$3.69 +0.11 (+3.10%)
As of 03:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Better Choice stock logo

Better Choice NYSE:SRXH

$1.54 -0.04 (-2.44%)
As of 03:09 PM Eastern

Better Choice Company Inc. operates as a pet health and wellness company. Its products portfolio includes naturally formulated kibble and canned dog and cat foods, freeze-dried raw dog foods and treats, vegan dog foods and treats, oral care products and supplements, as well as toppers, dental products, and chews. The company sells its products under Halo Holistic and Halo Elevate brands. It primarily sells its products through its online portals, as well as through online retailers and pet specialty retailers. The company has operations in the United States, Canada, and select Asian markets, including China. The company was formerly known as Sports Endurance, Inc. and changed its name to Better Choice Company Inc. in March 2019. Better Choice Company Inc. is based in Tampa, Florida.

Tharimmune stock logo

Tharimmune NASDAQ:THAR

$2.23 -0.05 (-2.19%)
As of 09/8/2026

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Upexi stock logo

Upexi NASDAQ:UPXI

$1.02 -0.02 (-2.31%)
As of 03:30 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas